Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 7/20 | 0.34 |
| ▸ | JAK3 | P52333 | 7/20 | 0.34 |
| ▸ | JAK1 | P23458 | 6/20 | 0.34 |
| ▸ | TYK2 | P29597 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160527 | 0.77 | MAP2K1 (0.53) | JAK1TYK2MAP2K1EPHB3 | |
| SCHEMBL9920334 | 0.74 | JAK1 (0.59) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920360 | 0.73 | EPHB3 (0.37) | MAP4K4JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920341 | 0.73 | JAK1 (0.58) | JAK2JAK3JAK1TYK2LCK | |
| SCHEMBL9920333 | 0.73 | JAK1 (0.58) | JAK2JAK3JAK1TYK2LCK | |
| SCHEMBL1160541 | 0.72 | JAK1 (0.60) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920347 | 0.71 | JAK1 (0.47) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920337 | 0.71 | JAK1 (0.50) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920346 | 0.70 | JAK1 (0.43) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9920446 | 0.70 | JAK2 (0.43) | JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | MAP4K4 79/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.